(Q33980960)

30 July 2017

1 reference

title

Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease (English)

1 reference

30 July 2017

0 references

0 references

Sanford I Finkel

1

1 reference

30 July 2017

publication date

1 July 2004

1 reference

30 July 2017

published in

Clinical Therapeutics

1 reference

30 July 2017

volume

26

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

980-990

1 reference

Introduction to behavioural and psychological symptoms of dementia (BPSD)

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Predictors of cognitive and functional progression in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Survival of outpatients with Alzheimer-type dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Acetylcholinesterase inhibition in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Treatment of Alzheimer Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Adverse effects associated with the use of donepezil in general practice in England.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

The efficacy of donepezil in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Donepezil in vascular dementia: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990172-5

7 January 2021

10.1016/S0149-2918(04)90172-5

Identifiers

DOI

1 reference

30 July 2017

1 reference